Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.04%
#2 Audiera Audiera +19.18%
#3 Geodnet Geodnet +10.71%
#4 Ocean Protocol Ocean Protocol +8.89%
#5 The Bitcoin Bull The Bitcoin Bull +6.72%
#6 Rollbit Coin Rollbit Coin +6.51%
#7 Quack AI Quack AI +5.98%
#8 Tutorial Tutorial +5.97%
#9 Cysic Cysic +5.70%
#10 LAB LAB +5.44%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Classifica tra le azioni #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Prezzo delle azioni
$1.11
Ultima sincronizzazione: 2026-08-17
Capitalizzazione di mercato
$10.06M
Variazione (1 giorno)
1.38%
Variazione (1 anno)
-55.98%
Paese
US
Scambia Lisata Therapeutics, Inc. (LSTA)

Categoria

Healthcare
Ricavi di Lisata Therapeutics, Inc. (LSTA)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Lisata Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Lisata Therapeutics, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE